Abstract | OBJECTIVE: DESIGN: Placebo-controlled, randomized study. SETTING: Patients were recruited from the Institute of Endocrine Cosmetics, Vienna, Austria. PATIENTS: INTERVENTIONS: MAIN OUTCOME MEASURES: Clinical grading according to acne severity and lesion counts as well as determinations of serum cyproterone acetate concentrations. RESULTS: After 3 months of therapy with topical cyproterone acetate, the decrease of mean facial acne grade from 1.57 to 0.67 was significantly better (P<.05) compared with placebo (which showed a change from 1.57 to 1.25), but not compared with oral medication (1.56 to 0.75) (P>.05). Lesion counts also decreased from 35.9 to 9.1 in the topical cyproterone acetate group compared with oral medication (45.4 to 15.5) (P>.05) and placebo (38.2 to 23.1) (P<.05). After topical cyproterone acetate treatment, serum cyproterone acetate concentrations were 10 times lower than those found after oral cyproterone acetate intake. CONCLUSIONS:
|
Authors | D M Gruber, M O Sator, E A Joura, E M Kokoschka, G Heinze, J C Huber |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 134
Issue 4
Pg. 459-63
(Apr 1998)
ISSN: 0003-987X [Print] United States |
PMID | 9554298
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgen Antagonists
- Drug Combinations
- Ethinyl Estradiol
- Cyproterone Acetate
|
Topics |
- Acne Vulgaris
(blood, drug therapy, pathology)
- Administration, Oral
- Administration, Topical
- Adult
- Androgen Antagonists
(administration & dosage, therapeutic use)
- Cyproterone Acetate
(administration & dosage, blood, therapeutic use)
- Drug Combinations
- Ethinyl Estradiol
(therapeutic use)
- Female
- Humans
- Treatment Outcome
|